NasdaqGS:ILMNLife Sciences
Should Illumina’s (ILMN) Return to Profitability and Raised Guidance Shift Investor Expectations?
Illumina reported a return to profitability in its second-quarter results ended June 29, 2025, with net income of US$235 million despite revenues decreasing to US$1,059 million from US$1,112 million a year earlier, and also raised its fiscal 2025 earnings guidance to forecast a smaller revenue decline.
The company completed its previously announced share repurchase program and launched the updated TruSight Oncology 500 assay, highlighting a dual focus on capital returns and ongoing product...